Normocarb Hf 35 is a drug owned by Dialysis Supplies Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 31, 2017. Details of Normocarb Hf 35's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5945449 | Sterile bicarbonate concentrate |
Oct, 2017
(7 years ago) |
Expired
|
FDA has granted several exclusivities to Normocarb Hf 35. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Normocarb Hf 35, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Normocarb Hf 35.
Exclusivity Information
Normocarb Hf 35 holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Normocarb Hf 35's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 26, 2013 |
US patents provide insights into the exclusivity only within the United States, but Normocarb Hf 35 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Normocarb Hf 35's family patents as well as insights into ongoing legal events on those patents.
Normocarb Hf 35's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Normocarb Hf 35's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 31, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Normocarb Hf 35 Generics:
There are no approved generic versions for Normocarb Hf 35 as of now.
Alternative Brands for Normocarb Hf 35
Normocarb Hf 35 which is used for treating acute kidney injury in continuous renal replacement therapy., has several other brand drugs in the same treatment category and using the same active ingredient (Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Dialysis Sups |
| |||
About Normocarb Hf 35
Normocarb Hf 35 is a drug owned by Dialysis Supplies Inc. It is used for treating acute kidney injury in continuous renal replacement therapy. Normocarb Hf 35 uses Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride as an active ingredient. Normocarb Hf 35 was launched by Dialysis Sups in 2006.
Approval Date:
Normocarb Hf 35 was approved by FDA for market use on 26 July, 2006.
Active Ingredient:
Normocarb Hf 35 uses Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride as the active ingredient. Check out other Drugs and Companies using Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride ingredient
Treatment:
Normocarb Hf 35 is used for treating acute kidney injury in continuous renal replacement therapy.
Dosage:
Normocarb Hf 35 is available in solution form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.21GM/100ML;3.97GM/100ML;8.3GM/100ML | SOLUTION | Prescription | INJECTION |